RU2014147625A - Прогнозирование рака молочной железы, предсказание подтипа прогестероновых рецепторов и предсказание ответа на лечение антипрогестином на основании генной экспрессии - Google Patents
Прогнозирование рака молочной железы, предсказание подтипа прогестероновых рецепторов и предсказание ответа на лечение антипрогестином на основании генной экспрессии Download PDFInfo
- Publication number
- RU2014147625A RU2014147625A RU2014147625A RU2014147625A RU2014147625A RU 2014147625 A RU2014147625 A RU 2014147625A RU 2014147625 A RU2014147625 A RU 2014147625A RU 2014147625 A RU2014147625 A RU 2014147625A RU 2014147625 A RU2014147625 A RU 2014147625A
- Authority
- RU
- Russia
- Prior art keywords
- gene
- expression
- sample
- group
- expression level
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract 52
- 230000000708 anti-progestin effect Effects 0.000 title claims abstract 21
- 239000003418 antiprogestin Substances 0.000 title claims abstract 21
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract 4
- 206010006187 Breast cancer Diseases 0.000 title 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 50
- 108090000623 proteins and genes Proteins 0.000 claims abstract 42
- -1 RASCD2 Proteins 0.000 claims abstract 34
- 201000011510 cancer Diseases 0.000 claims abstract 20
- 239000012472 biological sample Substances 0.000 claims abstract 19
- 239000000523 sample Substances 0.000 claims abstract 19
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims abstract 15
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims abstract 15
- 239000013068 control sample Substances 0.000 claims abstract 15
- 102100040634 Actin filament-associated protein 1-like 2 Human genes 0.000 claims abstract 10
- 102100024158 Cadherin-10 Human genes 0.000 claims abstract 10
- 101000892366 Homo sapiens Actin filament-associated protein 1-like 2 Proteins 0.000 claims abstract 10
- 101000762229 Homo sapiens Cadherin-10 Proteins 0.000 claims abstract 10
- 101000723759 Homo sapiens Zinc finger protein 26 Proteins 0.000 claims abstract 10
- 102100028392 Zinc finger protein 26 Human genes 0.000 claims abstract 10
- 208000035196 congenital hypomyelinating 2 neuropathy Diseases 0.000 claims abstract 10
- 102100026096 Claudin-8 Human genes 0.000 claims abstract 9
- 101000912659 Homo sapiens Claudin-8 Proteins 0.000 claims abstract 9
- 101000717344 Homo sapiens RNA-binding protein with multiple splicing 2 Proteins 0.000 claims abstract 9
- 101000707156 Homo sapiens SH2 domain-containing protein 4B Proteins 0.000 claims abstract 9
- 102100020795 RNA-binding protein with multiple splicing 2 Human genes 0.000 claims abstract 9
- 102100031769 SH2 domain-containing protein 4B Human genes 0.000 claims abstract 9
- 101001082864 Homo sapiens Peroxisomal membrane protein 4 Proteins 0.000 claims abstract 7
- 102100030555 Peroxisomal membrane protein 4 Human genes 0.000 claims abstract 7
- 210000004696 endometrium Anatomy 0.000 claims abstract 5
- 210000004556 brain Anatomy 0.000 claims abstract 3
- 210000004072 lung Anatomy 0.000 claims abstract 3
- 210000001672 ovary Anatomy 0.000 claims abstract 3
- 102000003998 progesterone receptors Human genes 0.000 claims abstract 3
- 108090000468 progesterone receptors Proteins 0.000 claims abstract 3
- 210000002307 prostate Anatomy 0.000 claims abstract 3
- 230000001225 therapeutic effect Effects 0.000 claims abstract 3
- 101001047043 Homo sapiens Kelch repeat and BTB domain-containing protein 11 Proteins 0.000 claims abstract 2
- 102100022827 Kelch repeat and BTB domain-containing protein 11 Human genes 0.000 claims abstract 2
- 108010061408 Autophagy-Related Protein 12 Proteins 0.000 claims 9
- 102000012035 Autophagy-Related Protein 12 Human genes 0.000 claims 9
- 102100040615 Homeobox protein MSX-2 Human genes 0.000 claims 9
- 101000967222 Homo sapiens Homeobox protein MSX-2 Proteins 0.000 claims 9
- 101001050607 Homo sapiens KH domain-containing, RNA-binding, signal transduction-associated protein 3 Proteins 0.000 claims 9
- 101001139112 Homo sapiens Krueppel-like factor 9 Proteins 0.000 claims 9
- 101000583692 Homo sapiens Pleckstrin homology-like domain family A member 1 Proteins 0.000 claims 9
- 101000596334 Homo sapiens TSC22 domain family protein 1 Proteins 0.000 claims 9
- 101000795338 Homo sapiens Tripartite motif-containing protein 51 Proteins 0.000 claims 9
- 101000788608 Homo sapiens Tubulin alpha-3D chain Proteins 0.000 claims 9
- 101000841331 Homo sapiens Urotensin-2B Proteins 0.000 claims 9
- 101000734339 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 claims 9
- 102100023428 KH domain-containing, RNA-binding, signal transduction-associated protein 3 Human genes 0.000 claims 9
- 102100020684 Krueppel-like factor 9 Human genes 0.000 claims 9
- 102100030887 Pleckstrin homology-like domain family A member 1 Human genes 0.000 claims 9
- 102100035051 TSC22 domain family protein 1 Human genes 0.000 claims 9
- 102100029700 Tripartite motif-containing protein 51 Human genes 0.000 claims 9
- 102100025236 Tubulin alpha-3D chain Human genes 0.000 claims 9
- 102100029096 Urotensin-2B Human genes 0.000 claims 9
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 claims 9
- 102100035226 GDP-fucose transporter 1 Human genes 0.000 claims 8
- 108091006955 SLC35C1 Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 101000788609 Homo sapiens Tubulin alpha-3E chain Proteins 0.000 claims 6
- 102100025220 Tubulin alpha-3E chain Human genes 0.000 claims 6
- 101710013801 KIAA0513 Proteins 0.000 claims 4
- 102100025702 Uncharacterized protein KIAA0513 Human genes 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000000636 Northern blotting Methods 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 238000007901 in situ hybridization Methods 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000010208 microarray analysis Methods 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 101150052863 THY1 gene Proteins 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639407P | 2012-04-27 | 2012-04-27 | |
| US61/639,407 | 2012-04-27 | ||
| PCT/US2013/032677 WO2013162776A1 (en) | 2012-04-27 | 2013-03-15 | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014147625A true RU2014147625A (ru) | 2016-06-20 |
Family
ID=48045769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014147625A RU2014147625A (ru) | 2012-04-27 | 2013-03-15 | Прогнозирование рака молочной железы, предсказание подтипа прогестероновых рецепторов и предсказание ответа на лечение антипрогестином на основании генной экспрессии |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10501800B2 (https=) |
| EP (1) | EP2841594A1 (https=) |
| JP (1) | JP2015516155A (https=) |
| KR (1) | KR20150028232A (https=) |
| AU (1) | AU2013252913A1 (https=) |
| CA (1) | CA2871590A1 (https=) |
| HK (1) | HK1208057A1 (https=) |
| IL (1) | IL235351A0 (https=) |
| MX (1) | MX2014013044A (https=) |
| NZ (1) | NZ701652A (https=) |
| PH (1) | PH12014502410A1 (https=) |
| RU (1) | RU2014147625A (https=) |
| WO (1) | WO2013162776A1 (https=) |
| ZA (1) | ZA201407853B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014013044A (es) | 2012-04-27 | 2015-06-23 | Univ Minnesota | Pronostico de cancer de mamas, prediccion de subtipo de receptor de progesterona y prediccion de respuesta a tratamiento de antiprogestina basado en la expresion de genes. |
| US20140363425A1 (en) * | 2013-03-13 | 2014-12-11 | J. Dinny Graham | Systems and methods for identifying cancers having activated progesterone receptors |
| US20150276767A1 (en) * | 2014-03-12 | 2015-10-01 | The University Of Sydney | Systems and methods for identifying cancers having activated progesterone receptors |
| CN113559075A (zh) | 2014-11-17 | 2021-10-29 | 康泰科思特生物制药公司 | 奥那司酮延长释放组合物和方法 |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| EP3389632A4 (en) | 2015-12-15 | 2019-11-06 | Context Biopharma Inc. | AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
| WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| US10942183B2 (en) | 2017-04-05 | 2021-03-09 | Regents Of The University Of Minnesota | Methods of detecting progesterone receptor and of detecting an expression level |
| EP3822368A1 (en) | 2019-11-14 | 2021-05-19 | Koninklijke Philips N.V. | Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP4121964A1 (en) * | 2020-03-17 | 2023-01-25 | Regeneron Pharmaceuticals, Inc. | Methods and systems for determining responders to treatment |
| JP7619556B2 (ja) * | 2020-10-08 | 2025-01-22 | 藤倉化成株式会社 | 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー |
| US20250005743A1 (en) * | 2023-06-30 | 2025-01-02 | Mackay Memorial Hospital | Method and system for identifying hormone receptor status |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750015B2 (en) * | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| AU2001271579A1 (en) | 2000-06-28 | 2002-01-08 | University Technology Corporation | Progesterone receptor-regulated gene expression and methods related thereto |
| MX2014013044A (es) | 2012-04-27 | 2015-06-23 | Univ Minnesota | Pronostico de cancer de mamas, prediccion de subtipo de receptor de progesterona y prediccion de respuesta a tratamiento de antiprogestina basado en la expresion de genes. |
-
2013
- 2013-03-15 MX MX2014013044A patent/MX2014013044A/es unknown
- 2013-03-15 KR KR20147033298A patent/KR20150028232A/ko not_active Withdrawn
- 2013-03-15 HK HK15108666.9A patent/HK1208057A1/xx unknown
- 2013-03-15 US US13/843,482 patent/US10501800B2/en active Active
- 2013-03-15 WO PCT/US2013/032677 patent/WO2013162776A1/en not_active Ceased
- 2013-03-15 EP EP13714144.6A patent/EP2841594A1/en not_active Withdrawn
- 2013-03-15 AU AU2013252913A patent/AU2013252913A1/en not_active Abandoned
- 2013-03-15 CA CA2871590A patent/CA2871590A1/en not_active Abandoned
- 2013-03-15 RU RU2014147625A patent/RU2014147625A/ru not_active Application Discontinuation
- 2013-03-15 NZ NZ701652A patent/NZ701652A/en not_active IP Right Cessation
- 2013-03-15 JP JP2015508975A patent/JP2015516155A/ja active Pending
-
2014
- 2014-10-27 IL IL235351A patent/IL235351A0/en unknown
- 2014-10-27 PH PH12014502410A patent/PH12014502410A1/en unknown
- 2014-10-28 ZA ZA2014/07853A patent/ZA201407853B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013252913A1 (en) | 2014-11-27 |
| WO2013162776A1 (en) | 2013-10-31 |
| US20130316992A1 (en) | 2013-11-28 |
| IL235351A0 (en) | 2014-12-31 |
| EP2841594A1 (en) | 2015-03-04 |
| ZA201407853B (en) | 2015-12-23 |
| US10501800B2 (en) | 2019-12-10 |
| KR20150028232A (ko) | 2015-03-13 |
| CA2871590A1 (en) | 2013-10-31 |
| HK1208057A1 (en) | 2016-02-19 |
| PH12014502410A1 (en) | 2015-01-12 |
| JP2015516155A (ja) | 2015-06-11 |
| MX2014013044A (es) | 2015-06-23 |
| NZ701652A (en) | 2016-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014147625A (ru) | Прогнозирование рака молочной железы, предсказание подтипа прогестероновых рецепторов и предсказание ответа на лечение антипрогестином на основании генной экспрессии | |
| Teixeira et al. | Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients | |
| Yue et al. | Polymorphism of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population | |
| Peng et al. | Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma | |
| JP2015516155A5 (https=) | ||
| Shi et al. | The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression | |
| Sun et al. | Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin | |
| Zhang et al. | Down-regulation of miR-320 associated with cancer progression and cell apoptosis via targeting Mcl-1 in cervical cancer | |
| Bai et al. | MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression | |
| Li et al. | MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9 | |
| ES2861316T3 (es) | Métodos para pronosticar cáncer de próstata | |
| Ji et al. | Long noncoding RNA HOTAIR: An oncogene in human cervical cancer interacting with MicroRNA-17-5p | |
| RU2015144212A (ru) | Использование биогенеза микрорнк в экзосомах для диагностики и лечения | |
| Huerta et al. | Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts | |
| Mokbel | Unlocking the power of the homing phenomenon: why breast conserving surgery outshines mastectomy in overall survival | |
| Villegas et al. | Identification of novel non-coding RNA-based negative feedback regulating the expression of the oncogenic transcription factor GLI1 | |
| Tanaka et al. | Tumor suppressive microRNA-138 inhibits metastatic potential via the targeting of focal adhesion kinase in Ewing's sarcoma cells | |
| Luo et al. | Correlation between periostin and SNCG and esophageal cancer invasion, infiltration and apoptosis | |
| CN107488733B (zh) | miR-133b在前列腺癌骨转移诊断、预测、治疗中的应用 | |
| Yu et al. | Insertion/deletion polymorphism in IL1A 3′‐UTR is associated with susceptibility to endometrial cancer in Chinese Han women | |
| An et al. | Association of E2F3 expression with clinicopathological features of Wilms’ tumors | |
| CN105624271A (zh) | 一种与结直肠癌相关的miRNA及其应用 | |
| Saadh et al. | Dual roles of long non-coding RNAs in thyroid cancer: regulation of programmed cell death pathways | |
| Wang et al. | A functional variant at miRNA-122 binding site in IL-1α 3′ UTR predicts risk of recurrence in patients with oropharyngeal cancer | |
| Guo et al. | Association of Casp3 microRNA target site (1049216) SNP with the risk and progress of cervical squamous cell carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171018 |